May 16th 2022, Broadleaf’s Joint Venture, Broadstar LLC, was awarded the Defense Health Agency (DHA) Omnibus IV IDIQ for market segment 2 to provide Research and Development Support Services.

Omnibus IV is a 10-year IDIQ, with a 1Billion dollar ceiling, and a period of performance between June 20th 2022 and June 19th 2032.

Categories: News